MOR Wealth Management LLC Makes New Investment in Astrazeneca Plc $AZN

Key Points

• MOR Wealth Management purchased a new stake in AstraZeneca, acquiring 5,727 shares in the fourth quarter valued at approximately $526,000.
• Positive late‑stage trial results for tozorakimab—which reduced COPD flare‑ups versus placebo—have driven optimism about near‑term commercialization and helped lift the stock.
• AstraZeneca has a market cap of about $292.45 billion, recently paid a $1.595 dividend (record Feb 20, paid Mar 23), and carries a consensus analyst rating of "Moderate Buy".

MOR Wealth Management LLC purchased a new stake in Astrazeneca Plc (NYSE:AZN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,727 shares of the company's stock, valued at approximately $526,000.

Several other hedge funds also recently modified their holdings of the company. Bank of America Corp DE boosted its stake in shares of Astrazeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company's stock valued at $2,503,614,000 after purchasing an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Astrazeneca by 2.3% during the 3rd quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company's stock worth $1,623,604,000 after buying an additional 466,745 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company's stock valued at $521,517,000 after buying an additional 582,183 shares during the period. Holocene Advisors LP raised its position in shares of Astrazeneca by 41.8% during the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company's stock worth $470,232,000 after acquiring an additional 1,807,565 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Astrazeneca by 13.1% during the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company's stock worth $438,342,000 after acquiring an additional 660,569 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

Astrazeneca Stock Up 0.1%

Shares of NYSE:AZN opened at $188.57 on Monday. Astrazeneca Plc has a twelve month low of $122.48 and a twelve month high of $212.71. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 0.51. The company has a market cap of $292.45 billion, a PE ratio of 32.48, a PEG ratio of 1.42 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca's dividend payout ratio is presently 66.26%.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of "Moderate Buy," which supports the stock’s upside but does not by itself explain today's move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc NYSE: AZN Receives Consensus Rating of "Moderate Buy" from Analysts

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings began coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They set a "buy (b)" rating for the company. TD Cowen reiterated a "buy" rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Citigroup started coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a "buy" rating on the stock. Guggenheim reissued a "buy" rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, Wall Street Zen upgraded shares of Astrazeneca from a "hold" rating to a "buy" rating in a research note on Friday, March 20th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.